As an influenza vaccine manufacturer Crucell is aware of the current situation in Mexico and other affected countries. Crucell is in active dialogue with the relevant governmental authorities and non governmental organizations (NGOs), while suitable actions to the situation are being decided. As an active member of the International Vaccine Supply Task Force and the International Federation of Pharmaceutical Manufacturers and Associations, Crucell will work with other industry members, health authorities and NGOs to respond as rapidly as possible and in accordance with key recommendations made by the World Health Organization (WHO). In response to a request from the Pan American Health Organization, Crucell is looking to mobilize remaining (limited) stocks of its 2008/2009 seasonal vaccine Inflexal^® V for supply to Mexico. Although at this stage it is not clear if existing seasonal flu vaccines induce protective immunity to the currently circulating H1N1 swine flu virus strain. The situation appears to be evolving rapidly, therefore Crucell's response will be tailored to support the public health needs, once more information becomes available, and as directed by organizations such as the WHO.

Crucell has an active influenza R&D program to improve the prevention and treatment of seasonal and pandemic influenza:

1. Crucell is testing new adjuvants and new routes of administration in humans for virosome-based pandemic influenza vaccines in the EU (Panfluvac program).
2. Sanofi Pasteur is using Crucell's PER.C6^® technology to produce the next generation influenza vaccines.
3. Crucell has discovered human monoclonal antibodies broadly protecting against H1 strains to which family the current swine flu virus belongs. The most potent and broadly reactive of these antibodies is currently being prepared for clinical testing.